PROLONGED DUAL ANTIPLATELET THERAPY AFTER MYOCARDIAL INFARCTION: WHAT THE RESULTS OF THE PEGASUS-TIMI 54 TRIAL SHOW
https://doi.org/10.20996/1819-6446-2017-13-4-558-564
Abstract
Prerequisites for the prolonged dual antiplatelet therapy after myocardial infarction are presented. The results of a large randomized placebo-controlled PEGASUS-TIMI 54 trial on the evaluation of efficacy and safety of prolonged use of a combination of acetylsalicylic acid and blocker P2Y12 platelet receptor, ticagrelor, in patients with high risk of thrombotic complications of atherosclerosis with a history of myocardial infarction 1-3 years ago are considered. The contribution of the results of this clinical trial in the modern understanding of the optimal use of antiplatelet agents in patients after myocardial infarction is analyzed.
About the Author
I. S. Yavelov
National Medical Research Center for Preventive Medicine
Russian Federation
Russian Federation
MD, PhD, Leading Researcher, Department of Clinical Cardiology and Molecular Genetics,
Petroverigsky per. 10, Moscow, 101990
References
1. Jernberg T., Hjelm H., Hasvold P., et al. Continued high CVD risk in myocardial infarction survivors: comparison of risk first and second year after MI - results from a Swedish nationwide study. Eur Heart J. 2014;35(suppl. 1):363.
2. Jernberg T., Hasvold P., Henriksson M., et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015;36:1163-70.
3. Fox K.A.A., Carruthers K.F., Dunbar D.R., et al. Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study). Eur Heart J. 2010;31:2755-64.
4. Cambou J.P., Simon T., Mulak G., et al, The French registry of Acute ST elevation or non-ST-elevation Myocardial Infarction (FAST-MI): study design and baseline characteristics. Arch Mal Coeur Vaiss. 2007;100:524-34.
5. Stone G.W., Maehara A., Lansky A.J., et al.; PROSPECT Investigators. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364:226-35.
6. Varenhorst C.,Johansson S., Hasvold P., et al. Culprit and Non-Culprit RecurrentIschemic Events in PostMyocardial Infarction Patients: Data From SWEDEHEART. Circulation. 2016;134:A13206.
7. Kereiakes D.J., Yeh R.W., Massaro J.M., et al. DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction. JACC. 2016;67:2492-502.
8. Mauri L., Kereiakes D.J., Yeh R.W., et al. Twelve or 30 months of dual antiplatelet therapy after drugeluting stents. N Engl J Med. 2014;371:2155-66.
9. Yeh R.W., Kereiakes D.J., Steg P.G., et al. Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. JACC. 2015;65:2211-21.
10. Udell J.A., Bonaca M.P., Collet J.P., et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J. 2016;37:390-9.
11. Nakatani D., Sakata Y., Suna S., et al.; Osaka Acute Coronary Insufficiency Study (OACIS) Investigators. Incidence, predictors, and subsequent mortality risk of recurrent myocardial infarction in patients following discharge for acute myocardial infarction. Circ J. 2013;77:439-46.
12. Figueras J., Missorici M., Lidón R.M., et al. Coincidental annual distribution of first and second acute myocardial infarction. Am J Cardiol. 2002;89:1416-20.
13. Nauta S.T., Deckers J.W., Akkerhuis K.M., et al. Short- and Long-Term Mortality After Myocardial Infarction in Patients With and Without Diabetes. Changes from 1985 to 2008. Diabetes Care. 2012;35:2043-7.
14. Romain A., Elbaz M., Simon T., et al. Prevalence, clinical proёle and 3-year survival of acute myocardial infarction patients with and without obstructive coronary lesions: The FAST-MI 2005 registry. Int J Cardiol. 2014;172:e247-e249.
15. Bhatt D.L., Eagle K.A., Ohman E.M.; REACH Registry Investigators. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304:1350-7.
16. Bonaca M.P., Bhatt D.L., Cohen M., et al., for the PEGASUS-TIMI 54 Steering Committee and Investigators. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. N Engl J Med. 2015;372:1791-800.
17. Bonaca M.P., Bhatt D.L., Steg P.G., et al. Ischaemic risk and efficacy of ticagrelorin relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. Eur Heart J. 2016;37:1133-42.
18. Bonaca M.P., Goto S., Bhatt D.L., et al. Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction. Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54). Circulation. 2016;134:861-71.
19. Wallentin L., Becker R.C., Budaj A., et al., for the PLATO Investigators. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2009;361:1045-57.
20. Bhatt D.L., Bonaca M.P., Bansilal S., et al. Reduction in Ischemic Events with Ticagrelor in Diabetic Patients: From the PEGASUS-TIMI 54 Trial. JACC. 2016;67:2732-40.
21. Magnani G., Storey R.F., Steg G., et al. Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. Eur Heart J. 2016;37:400-8.
22. Bonaca M.P., Bhatt D.L., Storey R.F., et al. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. JACC. 2016;67:2719-28.
23. Bansilal S., Bonaca M., Cornel J.H., et al. Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in patients with prior mi and multivessel coronary disease: insights from the PEGASUS-TIMI 54 trial. JACC. 2016;67:A2146.
24. Capodanno D., Capranzano P., Buccheri S., Tamburino C. Risk stratification for secondary prevention with ticagrelor and aspirin: A closer look to patient subsets from the PEGASUS-TIMI 54 trial. Int J Cardiol. 2015;201:276-8.
25. Bonaca M.P., Bhatt D.L., Oude Ophuis T., et al. Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial. JAMA Cardiol. 2016;1:425-32.
26. Roffi M., Patrono C., Collet J.P., et al. 2015ESCGuidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:267-315.
27. Correction to: 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable IschemicHeartDisease, 2013 ACCF/AHA Guideline forthe Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation. 2016 Sep 6;134(10):e192-4.
28. Bonaca M.P., Storey R.F, Theroux P., et al. Consistent Benefit of Ticagrelor Both Early and Late in Patients With Prior MI in PEGASUS-TIMI 54. Circulation. 2015;132:A19642.
Review
For citations:
Yavelov I.S. PROLONGED DUAL ANTIPLATELET THERAPY AFTER MYOCARDIAL INFARCTION: WHAT THE RESULTS OF THE PEGASUS-TIMI 54 TRIAL SHOW. Rational Pharmacotherapy in Cardiology. 2017;13(4):558-564. (In Russ.) https://doi.org/10.20996/1819-6446-2017-13-4-558-564
Views: 808
Email this article 